EP Patent

EP2528918B1 — 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators

Assigned to Nerviano Medical Sciences SRL · Expires 2014-09-10 · 12y expired

What this patent protects

Patent listed against Retevmo.

Drugs covered by this patent

Patent Metadata

Patent number
EP2528918B1
Jurisdiction
EP
Classification
—
Expires
2014-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Nerviano Medical Sciences SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.